Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805384 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL29564993 | 0.91 | KDM4E (0.83) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL9145815 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL6550349 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL30530607 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL534610 | 0.74 | KDM4E (0.58) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL9778876 | 0.72 | KDM4E (0.56) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL7113768 | 0.67 | KDM4E (0.50) | KDM4EALDH1A1MAPTPKM | |
| SCHEMBL7118211 | 0.65 | KDM4E (0.48) | KDM4EALDH1A1MAPT | |
| SCHEMBL7116688 | 0.65 | KDM4E (0.48) | KDM4EALDH1A1MAPTPKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | KDM4E 4738/4885ALDH1A1 4135/4885MAPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.